生物医药公司Immunic, Inc.正式宣布，任命在生物制药领域拥有丰富经验的迈克尔·A·潘扎拉博士（Michael A. Panzara, M.D., M.P.H.）担任首席医疗官一职。潘扎拉博士在药物研发和临床开发方面具备深厚资历，此次任命将强化Immunic在创新疗法开发领域的领导团队。
潘扎拉博士曾主导多项重大临床项目，并在神经科学、免疫学等治疗领域取得显著成果。他的加入有望加速Immunic管线药物的临床推进，并为公司战略规划注入新的专业视角。
这一人事变动彰显了Immunic持续加强研发实力、推进旗下候选药物全球开发的决心。公司表示，潘扎拉博士的行业经验和科学洞察将为其治疗自身免疫性疾病和炎症性疾病的创新疗法开发提供重要支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.